DVA
DaVita HealthCare Partners Inc
DaVita HealthCare Partners Inc historical holders
total: 9
Meritage Group DaVita HealthCare Partners Inc transactions over time
- Total transactions:
- 7
- New positions:
- 3
- Sold out:
- 3
- Added:
- 1
- Held since:
- 2024 Q1
- Held for:
- 2 quarters
- Latest activity:
- 2024 Q3
Nathaniel Simons has been an institutional investor in DaVita HealthCare Partners Inc (DVA) since 2016 Q4. According to 2026 Q1 report, Nathaniel Simons doesn't hold any shares. The fund/company first acquired DVA in 2016 Q4, initially purchasing 23,025 shares. Nathaniel Simons later completely sold out the position and reinvested in DVA again in 2024 Q1. Since the initial investment, Meritage Group has made 6 more transactions in this position.
When did Nathaniel Simons exit their DVA position?
Nathaniel Simons no longer holds DaVita HealthCare Partners Inc (DVA). They sold off their entire position in 2024 Q3, closing out an investment that began in 2016 Q4.
When did Nathaniel Simons first invest in DVA?
Nathaniel Simons first invested in DaVita HealthCare Partners Inc (DVA) in 2016 Q4 at the reported quarter-end price of $64.19 per share, acquiring 23,025 shares in their initial purchase.
What is Nathaniel Simons's average cost basis for DVA?
Based on historical transaction data, Nathaniel Simons's estimated cost basis for DaVita HealthCare Partners Inc (DVA) is approximately $138.07 per share. This represents their average reported price* across all buy transactions.
Has Nathaniel Simons reinvested in DVA after selling?
Yes, Nathaniel Simons has shown renewed interest in DaVita HealthCare Partners Inc (DVA). After completely selling their position, they reinitiated an investment in 2024 Q1, demonstrating continued conviction in this ticker.
Estimated cost basis*
- Weighted AVG buy price:
- $138.07
- Weighted AVG sell price:
- $138.57
DVA transactions history by Meritage Group
7 results
| Period |
% of portfolio |
Shares held after* |
Reported price* |
Value* |
% (shares) of activity |
% change to portfolio |
|---|---|---|---|---|---|---|
|
2024 Q3
|
0.00%
|
0
|
$138.57
|
|
-100% (-2,230)
|
-0.01%
|
|
2024 Q2
|
0.01%
|
2,230
|
$138.57
|
$309,011
|
+11.11% (+223)
|
+0%
|
|
2024 Q1
|
0.01%
|
2,007
|
$138.02
|
$277,000
|
new
|
+0.01%
|
|
2022 Q4
|
0.00%
|
0
|
$82.95
|
|
-100% (-2,592)
|
-0.01%
|
|
2022 Q3
|
0.01%
|
2,592
|
$82.95
|
$215,000
|
new
|
+0.01%
|
|
2017 Q1
|
0.00%
|
$64.19
|
-100% (-23,025)
|
|||
|
2016 Q4
|
0.05%
|
$64.19
|
new
|
|||
* Shares, change to shares, sold shares, shares held after: split-adjusted.
* Reported price: this doesn't represent the actual buy or sell price. It is the split-adjusted price of the security as of the last day of the reported period.
If the security is completely sold out, we show the reported split-adjusted price prior to the actual period.
If the security is completely sold out, we show the reported split-adjusted price prior to the actual period.
* Estimated cost basis: based on "Reported price*" (not earlier than 2013 Q2). Calculation starts from the latest "new buy" activity to the latest "close out" activity (if any).
* Value or Price: If the security is completely sold out, we show the reported value (or price) prior to the actual period.
* New buy or own: this means there is no earlier reporting (for us or in general). So we can't know if the actual purchase of the security happened at the reported period or earlier.